Corrigendum to "Polymer-based nanoparticles for oral insulin delivery: Revisited approaches",[Biotechnol Adv. 2015 Nov 1;33 (6 Pt 3):1342-1354] DOI:10.1016/j.biotechadv.2015.02.010.;Polymer-based nanoparticles for oral insulin delivery: Revisited approaches

Biotechnology Advances

Volumn 33, Issue 6, 2014, Pages 1342-1354

  Fonte, Pedro ^a,b   Araújo, Francisca ^a,b,c,d   Silva, Cátia ^b   Pereira, Carla ^c   Reis, Salette ^a   Santos, Hélder A ^d   Sarmento, Bruno ^b,c  

^a UNIVERSITY OF PORTO   (Portugal)

^b INSTITUTO DE INVESTIGAÇÃO E FORMAÇÃO AVANÇADA EM CIÊNCIAS E TECNOLOGIAS DA SAÚDE   (Portugal)

^c INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Chitosan; Diabetes; Insulin; Intestinal uptake; Oral delivery; Poly(lactic co glycolic acid); Polymeric nanoparticles

Indexed keywords

AMINO ACIDS; BIOCHEMISTRY; CHITOSAN; HYALURONIC ACID; INDUSTRIAL RESEARCH; MEDICAL PROBLEMS; NANOPARTICLES; PATIENT TREATMENT; TOXICITY;

CONVENIENT ALTERNATIVES; GASTROINTESTINAL TRACT; INTESTINAL PERMEATIONS; INTESTINAL UPTAKE; ORAL BIOAVAILABILITIES; ORAL DELIVERY; POLY LACTIC-CO-GLYCOLIC ACID; POLYMERIC NANOPARTICLES;

INSULIN;

BIOAVAILABILITY; BIOLOGICAL UPTAKE; BIOTECHNOLOGY; CHITIN; DIABETES; DISEASE PREVALENCE; DISEASE SEVERITY; ENCAPSULATION; ENZYME ACTIVITY; NANOPARTICLE; POLYMER; SAFETY;

ALGINIC ACID; CHITOSAN; DEXTRAN; DRUG CARRIER; HYALURONIC ACID; INSULIN; LACTIC ACID; NANOPARTICLE; POLY(GAMMA-GLUTAMIC ACID); POLYALLYLAMINE; POLYAMINE; POLYGLUTAMIC ACID; POLYLACTIC ACID; POLYMER;

ANALOGS AND DERIVATIVES; CHEMISTRY; DRUG DELIVERY SYSTEM; HUMAN; ORAL DRUG ADMINISTRATION; PROCEDURES;

ADMINISTRATION, ORAL; ALGINATES; CHITOSAN; DEXTRANS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; HYALURONIC ACID; INSULIN; LACTIC ACID; NANOPARTICLES; POLYAMINES; POLYGLUTAMIC ACID; POLYMERS;

EID: 84955203326     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2015.12.017     Document Type: Erratum

References (125)

1. Agarwal V, Reddy IK, Khan MA. Oral delivery of proteins: effect of chicken and duck ovomucoid on the stability of insulin in the presence of a-chymotrypsin and trypsin. Pharm Pharmacol Commun 2000;6:223-7.
2. Araújo F, Pereira C, Granja PL, Santos HA, Sarmento B. Functionalized nanoparticles for targeting the gastrointestinal apical membrane receptors. In: Vooght-Johnson RD, editor. Advances and Challenges in Oral Delivery of Macromolecules. Future Science Group; 2014a.
3. Araújo F, Shrestha N, Shahbazi M-A, Fonte P, Mäkilä EM, Salonen JJ, et al. The impact of nanoparticles on themucosal translocation and transport of GLP-1 across the intestinal epithelium. Biomaterials 2014b;35:9199-207.
4. Avadi MR, Jalali A, Sadeghi AM, Shamimi K, Bayati KH, Nahid E, et al. Diethyl methyl chitosan as an intestinal paracellular enhancer: ex vivo and in vivo studies. Int J Pharm 2005;293:83-9.
5. Avadi MR, Sadeghi AM, Mohammadpour N, Abedin S, Atyabi F, Dinarvand R, et al. Preparation and characterization of insulin nanoparticles using chitosan and Arabic gum with ionic gelation method. Nanomedicine 2010;6:58-63.
6. Avadi MR, Sadeghi AM, Mohamadpour Dounighi N, Dinarvand R, Atyabi F, Rafiee-Tehrani M. Ex vivo evaluation of insulin nanoparticles using chitosan and Arabic gum. ISRN Pharm 2011;2011:860109.
7. Banting FG, Best CH. The internal secretion of the pancreas. J Lab Clin Med 1922;7:251-66.
8. Bayat A, Dorkoosh FA, Dehpour AR, Moezi L, Larijani B, Junginger HE, et al. Nanoparticles of quaternized chitosan derivatives as a carrier for colon delivery of insulin: ex vivo and in vivo studies. Int J Pharm 2008a;356:259-66.
9. Bayat A, Larijani B, Ahmadian S, Junginger HE, Rafiee-Tehrani M. Preparation and characterization of insulin nanoparticles using chitosan and its quaternized derivatives. Nanomedicine 2008b;4:115-20.
10. Carino GP, Jacob JS, Mathiowitz E. Nanosphere based oral insulin delivery. J Control Release 2000;65:261-9.
11. Chalasani KB, Russell-Jones GJ, Jain AK, Diwan PV, Jain SK. Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles. J Control Release 2007a;122:141-50.
12. Chalasani KB, Russell-Jones GJ, Yandrapu SK, Diwan PV, Jain SK. A novel vitamin B12-nanosphere conjugate carrier system for peroral delivery of insulin. J Control Release 2007b;117:421-9.
13. Chaturvedi K, Ganguly K, Nadagouda MN, Aminabhavi TM. Polymeric hydrogels for oral insulin delivery. J Control Release 2013;165:129-38.
14. Chaudhury A, Das S. Recent advancement of chitosan-based nanoparticles for oral controlled delivery of insulin and other therapeutic agents. AAPS PharmSciTech 2011; 12:10-20.
15. Chen SC, Wu YC, Mi FL, Lin YH, Yu LC, Sung HW. A novel pH-sensitive hydrogel composed of N, O-carboxymethyl chitosan and alginate cross-linked by genipin for protein drug delivery. J Control Release 2004;96:285-300.
16. Chen MC, Sonaje K, Chen KJ, Sung HW. A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery. Biomaterials 2011;32:9826-38.
17. Chen MC, Mi FL, Liao ZX, Hsiao CW, Sonaje K, Chung MF, et al. Recent advances in chitosan-based nanoparticles for oral delivery of macromolecules. Adv Drug Deliv Rev 2013;65:865-79.
18. Choonara BF, Choonara YE, Kumar P, Bijukumar D, du Toit LC, Pillay V. A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules. Biotechnol Adv 2014;32:1269-82.
19. Conner SD, Schmid SL. Regulated portals of entry into the cell. Nature 2003;422:37-44.
20. Cooper GM. The cell surface. The Cell: A Molecular Approach. 2nd ed Sunderland (MA): Sinauer Associates; 2000.
21. Cui F, Shi K, Zhang L, Tao A, Kawashima Y. Biodegradable nanoparticles loaded with insulin-phospholipid complex for oral delivery: preparation, in vitro characterization and in vivo evaluation. J Control Release 2006;114:242-50.
22. Cui F, Tao A, Cun D, Zhang L, Shi K. Preparation of insulin loaded PLGA-Hp55 nanoparticles for oral delivery. J Pharm Sci 2007;96:421-7.
23. Damgé C, Maincent P, Ubrich N. Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats. J Control Release 2007;117:163-70.
24. Damgé C, Socha M, Ubrich N, Maincent P. Poly(e-caprolactone)/eudragit nanoparticles for oral delivery of aspart-insulin in the treatment of diabetes. J Pharm Sci 2010;99: 879-89.
25. Davaran S, Omidi Y, Rashidi MR, Anzabi M, Shayanfar A, Ghyasvand S, et al. Preparation and in vitro evaluation of linear and star-branched PLGA nanoparticles for insulin delivery. J Bioact Compat Polym 2008;23:115-31.
26. des Rieux A, Fievez V, Garinot M, Schneider YJ, Preat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release 2006;116:1-27.
27. des Rieux A, Pourcelle V, Cani PD, Marchand-Brynaert J, Preat V. Targeted nanoparticles with novel non-peptidic ligands for oral delivery. Adv Drug Deliv Rev 2013;65: 833-44.
28. Deutel B, GreindlM, Thaurer M, Bernkop-Schnurch A. Novel insulin thiomer nanoparticles: in vivo evaluation of an oral drug delivery system. Biomacromolecules 2008;9:278-85.
29. Du X, Zhang J, Zhang Y, Li S, Lin X, Tang X, et al. Decanoic acid grafted oligochitosan nanoparticles as a carrier for insulin transport in the gastrointestinal tract. Carbohydr Polym 2014;111:433-41.
30. Elsayed A, Al-Remawi M, Qinna N, Farouk A, Al-Sou'od KA, Badwan AA. Chitosan-sodium lauryl sulfate nanoparticles as a carrier system for the in vivo delivery of oral insulin. AAPS PharmSciTech 2011;12:958-64.
31. Fasano A, Uzzau S. Modulation of intestinal tight junctions by zonula occludens toxin permits enteral administration of insulin and other macromolecules in an animal model. J Clin Invest 1997;99:1158-64.
32. Florence AT. Issues in oral nanoparticle drug carrier uptake and targeting. J Drug Target 2004;12:65-70.
33. Fonte P, Soares S, Costa A, Andrade J, Seabra V, Reis S, et al. Effect of cryoprotectants on the porosity and stability of insulin-loaded PLGA nanoparticles after freeze-drying. Biomatter 2012;2:329-39.
34. Fonte P, Araujo F, Reis S, Sarmento B. Oral insulin delivery: how far are we? J Diabetes Sci Technol 2013;7:520-31.
35. Foss AC, Goto T, Morishita M, Peppas NA. Development of acrylic-based copolymers for oral insulin delivery. Eur J Pharm Biopharm 2004;57:163-9.
36. Gan Q, Wang T. Chitosan nanoparticle as protein delivery carrier-systematic examination of fabrication conditions for efficient loading and release. Colloids Surf B Biointerfaces 2007;59:24-34.
37. Goldberg M, Gomez-Orellana I. Challenges for the oral delivery of macromolecules. Nat Rev Drug Discov 2003;2:289-95.
38. Gowthamarajan K, Kulkarni G. Oral insulin: fact or fiction? Possibilities of achieving oral delivery for insulin. Resonance 2003;8:38-46.
39. HanL, ZhaoY, YinL, LiR, LiangY, HuangH, et al. Insulin-loaded pH-sensitive hyaluronic acid nanoparticles enhance transcellular delivery. AAPS PharmSciTech 2012;13:836-45.
40. Hejazi R, Amiji M. Chitosan-based gastrointestinal delivery systems. J Control Release 2003;89:151-65.
41. Herrero EP, Alonso MJ, Csaba N. Polymer-based oral peptide nanomedicines. Ther Deliv 2012;3:657-68.
42. Hillaireau H, Couvreur P. Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol Life Sci 2009;66:2873-96.
43. Hochman J, Artursson P. Mechanisms of absorption enhancement and tight junction regulation. J Control Release 1994;29:253-67.
44. Hossain S, Chowdhury EH, Akaike T. Nanoparticles and toxicity in therapeutic delivery: the ongoing debate. Ther Deliv 2011;2:125-32.
45. Hosseininasab S, Pashaei-Asl R, Khandaghi AA, Nasrabadi HT, Nejati-Koshki K, Akbarzadeh A, et al. Synthesis, characterization, and in vitro studies of PLGA-PEG nanoparticles for oral insulin delivery. Chem Biol Drug Des 2014;84:307-15.
46. http://www.accesspharma.com, 2014. [Access Pharmaceuticals web page].
47. http://www.nanomegamedical.com, 2014. [NanoMega Medical Corporation web page].
48. http://www.nodpharm.com, 2014. NOD Pharmaceuticals, Inc. web page.
49. Huang L, Xin J, Guo Y, Li J. A novel insulin oral delivery system assisted by cationic ß-cyclodextrin polymers. J Appl Polym Sci 2010;115:1371-9.
50. Hunter AC, Elsom J, Wibroe PP, Moghimi SM. Polymeric particulate technologies for oral drug delivery and targeting: a pathophysiological perspective. Nanomedicine 2012; 8(Suppl. 1):S5-S20.
51. Jain S, Rathi VV, Jain AK, Das M, Godugu C. Folate-decorated PLGA nanoparticles as a rationally designed vehicle for the oral delivery of insulin. Nanomedicine (Lond) 2012;7:1311-37.
52. Janes KA, Calvo P, Alonso MJ. Polysaccharide colloidal particles as delivery systems for macromolecules. Adv Drug Deliv Rev 2001;47:83-97.
53. Jang MH, Kweon MN, Iwatani K, Yamamoto M, Terahara K, Sasakawa C, et al. Intestinal villous M cells: an antigen entry site in the mucosal epithelium. Proc Natl Acad Sci U S A 2004;101:6110-5.
54. JelvehgariM, Zakeri-Milani P, Siahi-ShadbadMR, Loveymi BD, Nokhodchi A, Azari Z, et al. Development of pH-sensitive insulin nanoparticles using Eudragit L100-55 and chitosan with different molecular weights. AAPS PharmSciTech 2010;11:1237-42.
55. Jin Y, Song Y, Zhu X, Zhou D, Chen C, Zhang Z, et al. Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport. Biomaterials 2012;33:1573-82.
56. Kamei N, Morishita M, Takayama K. Importance of intermolecular interaction on the improvement of intestinal therapeutic peptide/protein absorption using cellpenetrating peptides. J Control Release 2009;136:179-86.
57. Lane ME, O'Driscoll CM, Corrigan OI. Quantitative estimation of the effects of bile salt surfactant systems on insulin stability and permeability in the rat intestine using a mass balance model. J Pharm Pharmacol 2005;57:169-75.
58. Li CL, Deng YJ. Oil-based formulations for oral delivery of insulin. J Pharm Pharmacol 2004;56:1101-7.
59. Li MG, LuWL, Wang JC, Zhang X, Wang XQ, Zheng AP, et al. Distribution, transition, adhesion and release of insulin loaded nanoparticles in the gut of rats. Int J Pharm 2007; 329:182-91.
60. Lin YH, Mi FL, Chen CT, ChangWC, Peng SF, Liang HF, et al. Preparation and characterization of nanoparticles shelled with chitosan for oral insulin delivery. Biomacromolecules 2007;8:146-52.
61. Lin YH, Sonaje K, Lin KM, Juang JH, Mi FL, Yang HW, et al. Multi-ion-crosslinked nanoparticles with pH-responsive characteristics for oral delivery of protein drugs. J Control Release 2008;132:141-9.
62. Liu H, Tang R, Pan WS, Zhang Y, Liu H. Potential utility of various protease inhibitors for improving the intestinal absorption of insulin in rats. J Pharm Pharmacol 2003;55: 1523-9.
63. Liu X, Liu C, ZhangW, Xie C, Wei G, LuW. Oligoarginine-modified biodegradable nanoparticles improve the intestinal absorption of insulin. Int J Pharm 2013;448:159-67.
64. Ma Z, Yeoh HH, LimLY. Formulation pHmodulates the interaction of insulinwith chitosan nanoparticles. J Pharm Sci 2002;91:1396-404.
65. Ma Z, Lim TM, Lim LY. Pharmacological activity of peroral chitosan-insulin nanoparticles in diabetic rats. Int J Pharm 2005;293:271-80.
66. Makhlof A, Tozuka Y, Takeuchi H. Design and evaluation of novel pH-sensitive chitosan nanoparticles for oral insulin delivery. Eur J Pharm Sci 2011;42:445-51.
67. Mesiha MS, Sidhom MB, Fasipe B. Oral and subcutaneous absorption of insulin poly(isobutylcyanoacrylate) nanoparticles. Int J Pharm 2005;288:289-93.
68. Morishita M, Peppas NA. Is the oral route possible for peptide and protein drug delivery? Drug Discov Today 2006;11:905-10.
69. Mukhopadhyay P, Mishra R, Rana D, Kundu PP. Strategies for effective oral insulin delivery with modified chitosan nanoparticles: a review. Prog Polym Sci 2012;37:1457-75.
70. Mukhopadhyay P, Sarkar K, Chakraborty M, Bhattacharya S, Mishra R, Kundu PP. Oral insulin delivery by self-assembled chitosan nanoparticles: In vitro and in vivo studies in diabetic animal model. Mater Sci Eng C 2013;33:376-82.
71. Muzzarelli R. Chemical and technological advances in chitins and chitosans useful for the formulation of biopharmaceuticals. In: Sarmento B, das Neves J, editors. Chitosanbased systems for biopharmaceuticals: delivery, targeting and polymer therapeutics. John Wiley & Sons, Ltd; 2012. p. 3-21.
72. Nielsen EJB, Yoshida S, Kamei N, Iwamae R, Khafagy E-S, Olsen J, et al. In vivo proof of concept of oral insulin delivery based on a co-administration strategy with the cellpenetrating peptide penetratin. J Control Release 2014;189:19-24.
73. Pan Y, Li YJ, Zhao HY, Zheng JM, Xu H, Wei G, et al. Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int J Pharm 2002;249:139-47.
74. Perera G, Greindl M, Palmberger TF, Bernkop-Schnürch A. Insulin-loaded poly(acrylic acid)-cysteine nanoparticles: stability studies towards digestive enzymes of the intestine. Drug Deliv 2009;16:254-60.
75. Plapied L, Duhem N, des Rieux A, Préat V. Fate of polymeric nanocarriers for oral drug delivery. Curr Opin Colloid Interface Sci 2011;16:228-37.
76. Pridgen EM, Alexis F, Farokhzad OC. Polymeric nanoparticle technologies for oral drug delivery. Clin Gastroenterol Hepatol 2014;12:1605-10.
77. Reis CP, Veiga F, Nunes P, Soares AF, Laranjeira T, Carvalho R, et al. Toxicological in vivo studies of an oral insulin nanosystem. Toxicol Lett 2007;172:S90-S.
78. Reis CP, Figueiredo IV, Carvalho RA, Jones J, Nunes P, Soares AF, et al. Toxicological assessment of orally delivered nanoparticulate insulin. Nanotoxicology 2008;2: 205-17.
79. Reix N, Parat A, Seyfritz E, Van Der Werf R, Epure V, Ebel N, et al. In vitro uptake evaluation in Caco-2 cells and in vivo results in diabetic rats of insulin-loaded PLGA nanoparticles. Int J Pharm 2012;437:213-20.
80. Rekha MR, Sharma CP. Synthesis and evaluation of lauryl succinyl chitosan particles towards oral insulin delivery and absorption. J Control Release 2009;135:144-51.
81. Rekha MR, Sharma CP. Oral delivery of therapeutic protein/peptide for diabetes-future perspectives. Int J Pharm 2013;440:48-62.
82. Sadeghi AM, Dorkoosh FA, Avadi MR, Saadat P, Rafiee-Tehrani M, Junginger HE. Preparation, characterization and antibacterial activities of chitosan, N-trimethyl chitosan (TMC) and N-diethylmethyl chitosan (DEMC) nanoparticles loaded with insulin using both the ionotropic gelation and polyelectrolyte complexation methods. Int J Pharm 2008a;355:299-306.
83. Sadeghi AM, Dorkoosh FA, Avadi MR, Weinhold M, Bayat A, Delie F, et al. Permeation enhancer effect of chitosan and chitosan derivatives: comparison of formulations as soluble polymers and nanoparticulate systems on insulin absorption in Caco-2 cells. Eur J Pharm Biopharm 2008b;70:270-8.
84. Sajeesh S, Sharma CP. Cyclodextrin-insulin complex encapsulated polymethacrylic acid based nanoparticles for oral insulin delivery. Int J Pharm 2006;325:147-54.
85. Sandri G, Bonferoni MC, Rossi S, Ferrari F, Boselli C, Caramella C. Insulin-loaded nanoparticles based on N-trimethyl chitosan: in vitro (Caco-2model) and ex vivo (excised rat jejunum, duodenum, and ileum) evaluation of penetration enhancement properties. AAPS PharmSciTech 2010;11:362-71.
86. Santander-Ortega MJ, Bastos-Gonzalez D, Ortega-Vinuesa JL, Alonso MJ. Insulin-loaded PLGA nanoparticles for oral administration: an in vitro physico-chemical characterization. J Biomed Nanotechnol 2009;5:45-53.
87. Sarmento B, Ribeiro A, Veiga F, Ferreira D. Development and characterization of new insulin containing polysaccharide nanoparticles. Colloids Surf B Biointerfaces 2006; 53:193-202.
88. Sarmento B, Ferreira DC, Jorgensen L, van deWeert M. Probing insulin's secondary structure after entrapment into alginate/chitosan nanoparticles. Eur J Pharm Biopharm 2007a;65:10-7.
89. Sarmento B, Ribeiro A, Veiga F, Ferreira D, Neufeld R. Oral bioavailability of insulin contained in polysaccharide nanoparticles. Biomacromolecules 2007b;8:3054-60.
90. Sarmento B, Ribeiro A, Veiga F, Sampaio P, Neufeld R, Ferreira D. Alginate/chitosan nanoparticles are effective for oral insulin delivery. Pharm Res 2007c;24:2198-206.
91. Sarmento B, Ribeiro AJ, Veiga F, Ferreira DC, Neufeld RJ. Insulin-loaded nanoparticles are prepared by alginate ionotropic pre-gelation followed by chitosan polyelectrolyte complexation. J Nanosci Nanotechnol 2007d;7:2833-41.
92. Sharma G, van der Walle CF, Ravi Kumar MNV. Antacid co-encapsulated polyester nanoparticles for peroral delivery of insulin: development, pharmacokinetics, biodistribution and pharmacodynamics. Int J Pharm 2013;440:99-110.
93. Singh R, Lillard Jr J. Nanoparticle-based targeted drug delivery. Exp Mol Pathol 2009;86: 215-23.
94. Smith JM, Dornish M, Wood EJ. Involvement of protein kinase C in chitosan glutamatemediated tight junction disruption. Biomaterials 2005;26:3269-76.
95. Socha M, Sapin A, Damgé C, Maincent P. Influence of polymers ratio on insulin-loaded nanoparticles based on poly-e-caprolactone and Eudragit® RS for oral administration. Drug Deliv 2009;16:430-6.
96. Sonaje K, Lin YH, Juang JH, Wey SP, Chen CT, Sung HW. In vivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery. Biomaterials 2009; 30:2329-39.
97. Sonaje K, Chen YJ, Chen HL, Wey SP, Juang JH, Nguyen HN, et al. Enteric-coated capsules filled with freeze-dried chitosan/poly(gamma-glutamic acid) nanoparticles for oral insulin delivery. Biomaterials 2010;31:3384-94.
98. Sonaje K, Chuang EY, Lin KJ, Yen TC, Su FY, TsengMT, et al. Opening of epithelial tight junctions and enhancement of paracellular permeation by chitosan: microscopic, ultrastructural, and computed-tomographic observations. Mol Pharm 2012;9:1271-9.
99. Sosnik A, das Neves J, Sarmento B. Mucoadhesive polymers in the design of nano-drug delivery systems for administration by non-parenteral routes: a review. Prog Polym Sci 2014;39:2030-75.
100. Still JG. Development of oral insulin: progress and current status. Diabetes Metab Res Rev 2002;18(Suppl. 1):S29-37.
101. Su FY, Lin KJ, Sonaje K, Wey SP, Yen TC, Ho YC, et al. Protease inhibition and absorption enhancement by functional nanoparticles for effective oral insulin delivery. Biomaterials 2012;33:2801-11.
102. Sun S, Liang N, Piao H, Yamamoto H, Kawashima Y, Cui F. Insulin-S.O. (sodium oleate) complex-loaded PLGA nanoparticles: formulation, characterization and in vivo evaluation. J Microencapsul 2010;27:471-8.
103. Sung HW, Sonaje K, Liao ZX, Hsu LW, Chuang EY. pH-responsive nanoparticles shelled with chitosan for oral delivery of insulin: from mechanism to therapeutic applications. Acc Chem Res 2012;45:619-29.
104. Thompson CJ, Tetley L, Uchegbu IF, Cheng WP. The complexation between novel comb shaped amphiphilic polyallylamine and insulin-towards oral insulin delivery. Int J Pharm 2009;376:46-55.
105. Thompson CJ, Tetley L, ChengWP. The influence of polymer architecture on the protective effect of novel comb shaped amphiphilic poly(allylamine) against in vitro enzymatic degradation of insulin-towards oral insulin delivery. Int J Pharm 2010;383:216-27.
106. Thompson CJ, ChengW, Gadad P, Skene K, Smith M, Smith G, et al. Uptake and transport of novel amphiphilic polyelectrolyte-insulin nanocomplexes by Caco-2 cells-towards oral insulin. Pharm Res 2011;28:886-96.
107. Tyagi C, Tomar L, Kumar P, Choonara YE, Toit LD, Singh H, et al. pH responsive polymeric nanoparticles for oral insulin delivery. Int J Pharm Pharmacol Tech 2012:1.
108. van der Merwe SM, Verhoef JC, Verheijden JH, Kotze AF, Junginger HE. Trimethylated chitosan as polymeric absorption enhancer for improved peroral delivery of peptide drugs. Eur J Pharm Biopharm 2004;58:225-35.
109. Verheul RJ, Amidi M, van der Wal S, van Riet E, Jiskoot W, Hennink WE. Synthesis, characterization and in vitro biological properties of O-methyl free N, N, N-trimethylated chitosan. Biomaterials 2008;29:3642-9.
110. Werle M, Takeuchi H, Bernkop-Schnurch A. Modified chitosans for oral drug delivery. J Pharm Sci 2009;98:1643-56.
111. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011;94:311-21.
112. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53.
113. Woitiski CB, Neufeld RJ, Veiga F, Carvalho RA, Figueiredo IV. Pharmacological effect of orally delivered insulin facilitated by multilayered stable nanoparticles. Eur J Pharm Sci 2010;41:556-63.
114. Woitiski CB, Sarmento B, Carvalho RA, Neufeld RJ, Veiga F. Facilitated nanoscale delivery of insulin across intestinal membrane models. Int J Pharm 2011;412:123-31.
115. Woitiski CB, Neufeld RJ, Soares AF, Figueiredo IV, Veiga FJ, Carvalho RA. Evaluation of hepatic glucose metabolismvia gluconeogenesis and glycogenolysis after oral administration of insulin nanoparticles. Drug Dev Ind Pharm 2012;38:1441-50.
116. Wu ZM, Ling L, Zhou LY, Guo XD, Jiang W, Qian Y, et al. Novel preparation of PLGA/HP55 nanoparticles for oral insulin delivery. Nanoscale Res Lett 2012a;7:299.
117. Wu ZM, Zhou L, Guo XD, Jiang W, Ling L, Qian Y, et al. HP55-coated capsule containing PLGA/RS nanoparticles for oral delivery of insulin. Int J Pharm 2012b;425:1-8.
118. Xiong XY, Li YP, Li ZL, Zhou CL, Tam KC, Liu ZY, et al. Vesicles from pluronic/poly(lactic acid) block copolymers as new carriers for oral insulin delivery. J Control Release 2007;120:11-7.
119. Xiong XY, Li QH, Li YP, Guo L, Li ZL, Gong YC. Pluronic P85/poly(lactic acid) vesicles as novel carrier for oral insulin delivery. Colloids Surf B Biointerfaces 2013;111:282-8.
120. Yang J, Sun H, Song C. Preparation, characterization and in vivo evaluation of pH-sensitive oral insulin-loaded poly(lactic-co-glycolicacid) nanoparticles. Diabetes Obes Metab 2012;14:358-64.
121. Yeh TH, Hsu LW, Tseng MT, Lee PL, Sonjae K, Ho YC, et al. Mechanismand consequence of chitosan-mediated reversible epithelial tight junction opening. Biomaterials 2011;32: 6164-73.
122. Yin L, Ding J, He C, Cui L, Tang C, Yin C. Drug permeability andmucoadhesion properties of thiolated trimethyl chitosan nanoparticles in oral insulin delivery. Biomaterials 2009; 30:5691-700.
123. Zhang N, Li J, Jiang W, Ren C, Xin J, Li K. Effective protection and controlled release of insulin by cationic beta-cyclodextrin polymers from alginate/chitosan nanoparticles. Int J Pharm 2010;393:212-8.
124. Zhang X, Sun M, Zheng A, Cao D, Bi Y, Sun J. Preparation and characterization of insulinloaded bioadhesive PLGA nanoparticles for oral administration. Eur J PharmSci 2012; 45:632-8.
125. Zhang Y, Wu X, Meng L, Zhang Y, Ai R, Qi N, et al. Thiolated Eudragit nanoparticles for oral insulin delivery: preparation, characterization and in vivo evaluation. Int J Pharm 2012;436:341-50.